{"nctId":"NCT00760617","briefTitle":"Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older","startDateStruct":{"date":"2008-10-06"},"conditions":["Influenza"],"count":526,"armGroups":[{"label":"New generation influenza vaccine GSK2186877A Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Bio's influenza vaccine GSK2186877A"]},{"label":"Fluarix elderly Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Fluarix"]},{"label":"Fluarix young Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Fluarix"]}],"interventions":[{"name":"GSK Bio's influenza vaccine GSK2186877A","otherNames":[]},{"name":"Fluarix","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.\n* A male or female aged 18-41 years or ≥65 years at the time of the vaccination and who participated in the 110847 study and completed the 6 month follow-up.\n* Written informed consent obtained from the subject.\n* Fee of acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study.\n* Female subjects must be of non-childbearing potential.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period.\n* Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of an influenza vaccine other than the study vaccines or of a vaccine not foreseen in the study protocol during the entire study period.\n* Vaccination against influenza since January 2008 with a seasonal influenza vaccine.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* History of hypersensivity to a previous dose of influenza vaccine.\n* History of allergy or reactions likely to be exacerbated by any component of the vaccine(s).\n* Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or pre-existing laboratory screening tests.\n* Acute disease at the time of enrolment.\n* Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study.\n* Any medical conditions in which IM injections are contraindicated.\n* Lactating female, female planning to become pregnant or planning to discontinue contraceptive precautions.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)","description":"Grade 3 ecchymosis, redness and swelling was greater than or equal to 100 millimeter (mm) i.e. ≥ 100 mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Duration of Solicited Local AEs","description":"Duration was defined as number of days with any grade of local symptoms and grade for quantifiable symptoms: ecchymosis, redness and swelling was greater than (\\>) 20mm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs","description":"Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature \\>40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to vaccination, grade 3 was defined as a general symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Duration of Solicited General AEs","description":"Duration was defined as number of days with any grade of general symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"1.5","spread":null},{"groupId":"OG002","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs","description":"Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as possibly related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 0 to 20","description":"For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 21 to 179","description":"For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Disease (AID)","description":"AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoiimune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 to Day 20","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 to Day 179","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 180 to Day 209","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21","description":"Antibody titers were expressed as Geometric mean titres (GMTs) with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":null},{"groupId":"OG001","value":"22.9","spread":null},{"groupId":"OG002","value":"43.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null},{"groupId":"OG001","value":"57.5","spread":null},{"groupId":"OG002","value":"164.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"22.8","spread":null},{"groupId":"OG002","value":"28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243.9","spread":null},{"groupId":"OG001","value":"134.8","spread":null},{"groupId":"OG002","value":"171.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126.5","spread":null},{"groupId":"OG001","value":"159.9","spread":null},{"groupId":"OG002","value":"192.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"519.0","spread":null},{"groupId":"OG001","value":"402.5","spread":null},{"groupId":"OG002","value":"711.5","spread":null}]}]}]},{"type":"SECONDARY","title":"HI Antibody Titers at Day 180","description":"Antibody titers were expressed as GMTs with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":null},{"groupId":"OG001","value":"27.7","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"69.9","spread":null},{"groupId":"OG002","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"278.7","spread":null},{"groupId":"OG001","value":"255.7","spread":null},{"groupId":"OG002","value":"463.3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Subjects Seropositive to HI Antibodies at Day 0 and 21","description":"Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"125","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"116","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Subjects Seropositive to HI Antibodies at Day 180","description":"Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"125","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Subjects Seroconverted to HI Antibodies at Day 21","description":"Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre less than (\\<) 1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Subjects Seroconverted to HI Antibodies at Day 180","description":"Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre \\<1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"HI Antibody Seroconversion Factor (SCF) at Day 21","description":"SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"HI Antibody SCF at Day 180","description":"SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"2.9","spread":null},{"groupId":"OG002","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Subjects Seroprotected to HI Antibodies at Day 0 and Day 21","description":"Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"236","spread":null},{"groupId":"OG001","value":"136","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Subjects Seroprotected to HI Antibodies at Day 180","description":"Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"193","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]}]},{"type":"SECONDARY","title":"The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21","description":"The markers assessed were CD4-ALL DOUBLES, CD40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"751.28","spread":"492.55"},{"groupId":"OG001","value":"682.47","spread":"759.31"},{"groupId":"OG002","value":"1179.17","spread":"1031.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1431.41","spread":"679.60"},{"groupId":"OG001","value":"972.14","spread":"1204.18"},{"groupId":"OG002","value":"1513.30","spread":"798.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"451.86","spread":"419.39"},{"groupId":"OG001","value":"444.42","spread":"578.82"},{"groupId":"OG002","value":"743.45","spread":"552.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"912.85","spread":"496.53"},{"groupId":"OG001","value":"592.66","spread":"518.19"},{"groupId":"OG002","value":"912.28","spread":"476.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"828.74","spread":"840.19"},{"groupId":"OG001","value":"679.28","spread":"702.37"},{"groupId":"OG002","value":"1045.61","spread":"510.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1361.30","spread":"799.10"},{"groupId":"OG001","value":"935.28","spread":"1130.22"},{"groupId":"OG002","value":"1403.64","spread":"580.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"694.63","spread":"452.67"},{"groupId":"OG001","value":"616.27","spread":"682.26"},{"groupId":"OG002","value":"1127.82","spread":"946.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1305.74","spread":"622.93"},{"groupId":"OG001","value":"855.81","spread":"974.19"},{"groupId":"OG002","value":"1379.47","spread":"735.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392.35","spread":"368.33"},{"groupId":"OG001","value":"361.18","spread":"498.91"},{"groupId":"OG002","value":"646.92","spread":"542.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"803.34","spread":"459.33"},{"groupId":"OG001","value":"543.41","spread":"463.96"},{"groupId":"OG002","value":"816.08","spread":"447.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"775.18","spread":"754.90"},{"groupId":"OG001","value":"630.27","spread":"630.81"},{"groupId":"OG002","value":"959.42","spread":"465.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1230.63","spread":"731.08"},{"groupId":"OG001","value":"850.96","spread":"901.02"},{"groupId":"OG002","value":"1275.70","spread":"508.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"430.40","spread":"373.24"},{"groupId":"OG001","value":"338.29","spread":"613.41"},{"groupId":"OG002","value":"777.72","spread":"837.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"839.94","spread":"536.38"},{"groupId":"OG001","value":"481.04","spread":"976.79"},{"groupId":"OG002","value":"985.11","spread":"713.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282.79","spread":"321.42"},{"groupId":"OG001","value":"301.64","spread":"426.04"},{"groupId":"OG002","value":"501.13","spread":"482.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"628.36","spread":"400.49"},{"groupId":"OG001","value":"399.84","spread":"387.97"},{"groupId":"OG002","value":"638.93","spread":"418.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"447.23","spread":"708.32"},{"groupId":"OG001","value":"299.25","spread":"441.05"},{"groupId":"OG002","value":"681.49","spread":"413.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"800.89","spread":"648.91"},{"groupId":"OG001","value":"478.15","spread":"851.02"},{"groupId":"OG002","value":"934.53","spread":"471.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"645.57","spread":"445.17"},{"groupId":"OG001","value":"542.90","spread":"700.45"},{"groupId":"OG002","value":"1033.28","spread":"884.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1176.29","spread":"568.05"},{"groupId":"OG001","value":"816.63","spread":"1114.87"},{"groupId":"OG002","value":"1259.69","spread":"691.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"385.93","spread":"375.33"},{"groupId":"OG001","value":"392.63","spread":"488.21"},{"groupId":"OG002","value":"599.02","spread":"523.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"745.33","spread":"428.75"},{"groupId":"OG001","value":"505.78","spread":"459.04"},{"groupId":"OG002","value":"745.61","spread":"444.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"711.32","spread":"760.06"},{"groupId":"OG001","value":"547.71","spread":"646.50"},{"groupId":"OG002","value":"852.51","spread":"479.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1112.52","spread":"725.72"},{"groupId":"OG001","value":"778.12","spread":"1034.69"},{"groupId":"OG002","value":"1156.73","spread":"494.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"606.82","spread":"442.61"},{"groupId":"OG001","value":"610.09","spread":"669.96"},{"groupId":"OG002","value":"900.67","spread":"914.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1057.44","spread":"568.35"},{"groupId":"OG001","value":"749.70","spread":"1068.11"},{"groupId":"OG002","value":"1096.74","spread":"689.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"405.12","spread":"403.06"},{"groupId":"OG001","value":"414.27","spread":"508.57"},{"groupId":"OG002","value":"575.28","spread":"509.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"740.68","spread":"448.67"},{"groupId":"OG001","value":"449.51","spread":"463.77"},{"groupId":"OG002","value":"685.63","spread":"429.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"646.27","spread":"718.92"},{"groupId":"OG001","value":"558.87","spread":"591.29"},{"groupId":"OG002","value":"818.77","spread":"441.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1021.43","spread":"690.24"},{"groupId":"OG001","value":"715.45","spread":"973.99"},{"groupId":"OG002","value":"1023.28","spread":"475.97"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":266},"commonTop":["Pain","Fatigue","Headache","Myalgia","Shivering"]}}}